Alx Oncology Holdings (ALXO) EBT Margin (2019 - 2020)
Alx Oncology Holdings recorded quarterly EBT Margin of 2146.3% in Q2 2020, down 157.95% quarter-over-quarter from 832.06% in Q1 2020, and down 182282.0% year-over-year from N/an in Q3 2019.
Alx Oncology Holdings' EBT Margin history runs 2 years deep, the most recent figure standing at 2146.3% for Q2 2020.
- In Q2 2020, EBT Margin fell 182282.0% year-over-year to 2146.3%; the TTM figure through Mar 2021 stood at 3451.99% (down 297127.0% YoY), while the FY2020 annual figure was 800.08%, down 38261.0% from the prior year.
- EBT Margin came in at 2146.3% for Q2 2020 at Alx Oncology Holdings, down from 832.06% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 241.72% in Q3 2019 to a low of 2146.3% in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -2,146.30% |
| Mar 31, 2020 | -832.06% |
| Dec 31, 2019 | -706.35% |
| Sep 30, 2019 | -241.72% |
| Jun 30, 2019 | -323.47% |